Compare Ascendis Pharma A/S (ASND) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Kinross Gold Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Kinross Gold Corporation trades at $23.91 (market cap $28.72B). The key difference: Kinross Gold Corporation is the larger of the two by market cap, and Kinross Gold Corporation pays a 0.6% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KGC | |
|---|---|---|
Market Cap | $17.74B | $28.72B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $38.06 |
52-Week Low | $163.32 | $15.33 |
Enterprise Value | $18.11B | $27.28B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
KGC trades at $24.14, down 0.25% on the day, with a bearish technical signal from moving averages. The company shows strong fundamentals, with revenue growing from $3.5B in 2022 to $7.05B in 2025 and net income surging to $2.39B. Valuation ratios are attractive, including a P/E of 10.27 and EV/EBITDA of 5.3. Recent earnings have consistently beaten expectations, and a dividend of $0.04 per share was declared for H1-26.
The outlook is positive due to robust cash flow growth, a healthy balance sheet, and analyst consensus favoring a buy rating with a $36.25 price target. Key risks include potential margin pressure from rising costs and broader market volatility affecting gold prices. The stock presents a value opportunity if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
